GlassScriptPhysician profile
Murray Richard Berkowitz
NPI 1306997861
$2,321.08
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
See the full distribution for Neuromusculoskeletal Medicine & OMM
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,480 · 2022: $605 · 2023: $236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $236.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $235.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $307.49 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $289.56 | 2021-2022 | |
| Abbvie INC. | $254.83 | 2021-2023 | Vraylar |
| Abbott Laboratories | $212.77 | 2021 | |
| Novo Nordisk INC | $199.81 | 2021-2023 | Rybelsus, Ozempic, Wegovy |
| Eisai INC. | $147.75 | 2021 | |
| Corium, LLC | $120.30 | 2022-2023 | Azstarys |
| Amgen INC. | $99.45 | 2021-2023 | Repatha |
| Argenx US, INC. | $78.23 | 2022 | |
| Bausch Health US, LLC | $72.08 | 2022-2023 | Wellbutrin, Aplenzin |
| Astrazeneca Pharmaceuticals LP | $70.98 | 2021-2023 | Breztri |
| Jazz Pharmaceuticals INC. | $63.98 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $52.42 | 2022-2023 | Rexulti |
| Lundbeck LLC | $46.84 | 2022-2023 | Rexulti |
| Esperion Therapeutics, INC. | $42.58 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $40.81 | 2022-2023 | Seglentis |
| Dexcom, INC. | $32.93 | 2021-2023 | Dexcom G6 Transmitter |
| Ibsa Pharma INC. | $24.14 | 2021 | |
| Arbor Pharmaceuticals, INC. | $23.78 | 2021 | |
| Ucb, INC. | $19.98 | 2023 | Cimzia |
| Pfizer INC. | $19.96 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.91 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.07 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.30 | 2021 | |
| Lilly USA, LLC | $15.40 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $15.19 | 2022 | |
| Melinta Therapeutics, LLC | $14.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Murray Berkowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.